However, in a small randomized Phase II trial with 35 recurrent glioblastoma patients, the administration of the PD-1 inhibitor pembrolizumab before and after surgery significantly prolonged overall survival compared with adjuvant administration alone: 13.7 vs. 7.5 months, respectively [20]. The gene discussed is PDCD1; the disease is glioblastoma.